PointState Capital’s Bio-Rad Laboratories Class A BIO Stock Holding History

PointState Capital’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-4,500	Closed	-$3.36M	–	127
2021 Q3	$3.36M	Sell	4,500 -5,500	-55%	-$4.12M	0.06%	111
2021 Q2	$6.44M	Buy	+10,000	New	+$6.09M	0.11%	87
2018 Q3	–	Sell	-64,448	Closed	-$18.6M	–	145
2018 Q2	$18.6M	Hold	64,448	–	–	0.21%	82
2018 Q1	$16.1M	Buy	64,448 +5,754	+10%	+$1.47M	0.18%	80
2017 Q4	$14M	Sell	58,694 -9,906	-14%	-$2.4M	0.14%	89
2017 Q3	$15.2M	Buy	+68,600	New	+$15.4M	0.13%	94
2017 Q2	–	Sell	-20,100	Closed	-$4.01M	–	139
2017 Q1	$4.01M	Buy	+20,100	New	+$3.87M	0.04%	114

Other funds holding BIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

PointState Capital's BIO Position: Q4 2021 in Review

PointState Capital sold out of Bio-Rad Laboratories Class A (BIO) in Q4 2021, closing a stake of 4,500 shares — an estimated $3.36M sold.

PointState Capital first reported a position in BIO in Q1 2017 and held it in 7 quarters. The position peaked at $18.6M in Q2 2018. 533 funds tracked by Wall St. Rank hold BIO as of Q4 2021.

PointState Capital reported no remaining Bio-Rad Laboratories Class A position as of Q4 2021 after selling out during the quarter.
PointState Capital sold 4,500 Bio-Rad Laboratories Class A shares in Q4 2021, an estimated $3.36M.
PointState Capital first reported a position in Bio-Rad Laboratories Class A in Q1 2017 and held it in 7 quarters.
PointState Capital's Bio-Rad Laboratories Class A position peaked at $18.6M in Q2 2018.
533 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2021.

Based on PointState Capital's 13F filing for Q4 2021, filed 11 Feb 2022.